journal article·2026-12-31Open access

The unmasking of two-faced portrait in sorafenib-resistant surroundings via systems pharmacology concept: a brightness or a silhouette

Ki-Kwang Oh, Goo-Hyun Kwon, Jung-A Eom, Kyeong Jin Lee, Dong Joon Kim, Ki-Tae Suk

Abstract

This study aimed to identify novel key targets and mechanisms for repurposing strategies and mitigating sorafenib (SFB) resistance using the GEO transcriptomic dataset GSE94550 within a systems pharmacology framework. Potential counteracting molecules against SFB were retrieved from chemical repositories, followed by molecular docking tests (MDT), Kaplan–Meier survival analysis, and density functional theory (DFT) assessments to evaluate therapeutic potential. PPI networks were constructed using STRING and R to characterize the relationships between upregulated and downregulated genes. The most relevant signalling pathways associated with major targets were determined to elucidate the upstream regulatory mechanisms. Among the differentially expressed genes, APOB emerged as a pivotal regulator (log2FC ≥ +2 or ≤ −2), modulating fifteen genes, including eleven upregulated and four downregulated nodes. At stricter thresholds (log2FC ≥ +3 or ≤ −3 and ≥ +4 or ≤ −4), CD44 was identified as a key upregulated target. Its inhibition – particularly by verbacoside – was strongly associated with suppression of the ECM–receptor interaction pathway, suggesting a significant therapeutic axis. This study illuminates the molecular landscape of SFB-resistant environments through an integrative network approach and highlights verbacoside as a promising agent capable of attenuating SFB resistance, supporting its potential role in combination therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Melanoma and MAPK Pathways · Lung Cancer Treatments and Mutations · Psoriasis: Treatment and Pathogenesis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Liver and Digestive Diseases, College of Medicine, Hallym University

Funding

Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology · Bio Industrial Technology Development Program funded by the Ministry of Trade, Industry and Energy · Hallym University Research Fund · The Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology · Korea Institute for Advancement of Technology funded by the Ministry of Trade, Industry and Energy

References (79)

Show source-provided references
1. 10.1517/17460441.2015.100619410.1517/17460441.2015.1006194 ↗
2. 10.3748/WJG.V29.I17.257110.3748/WJG.V29.I17.2571 ↗
3. 10.3390/cancers1623394410.3390/cancers16233944 ↗
4. 10.3390/biomedicines1104102010.3390/biomedicines11041020 ↗
5. 10.3390/curroncol2908043410.3390/curroncol29080434 ↗
6. 10.1080/13543784.2022.207272610.1080/13543784.2022.2072726 ↗
7. 10.1038/S12276-018-0159-110.1038/S12276-018-0159-1 ↗
8. 10.1158/1535-7163.MCT-13-1043/85281/AM/INHIBITION-OF-AKT-REVERSES-THE-ACQUIRED-RESISTANCE10.1158/1535-7163.MCT-13-1043/85281/AM/INHIBITION-OF-AKT-REVERSES-THE-ACQUIRED-RESISTANCE ↗
9. 10.1016/J.DRUP.2012.10.00310.1016/J.DRUP.2012.10.003 ↗
10. 10.3390/CELLS809101310.3390/CELLS8091013 ↗
11. Quality OH. Gene Expression profiling tests for early-stage invasive breast cancer: a health technology assessment. Ont Health Technol. Assess. Ser. 2020;20:1.
12. 10.1016/J.GENDIS.2022.02.00710.1016/J.GENDIS.2022.02.007 ↗
13. 10.3389/FIMMU.2024.149254610.3389/FIMMU.2024.1492546 ↗
14. 10.3390/ijms2217945110.3390/ijms22179451 ↗
15. 10.1038/s41467-022-31430-010.1038/s41467-022-31430-0 ↗
16. 10.1038/s41392-021-00780-410.1038/s41392-021-00780-4 ↗
17. 10.3390/IJMS25221240210.3390/IJMS252212402 ↗
18. 10.1186/S13148-018-0587-810.1186/S13148-018-0587-8 ↗
19. 10.1016/J.TRECAN.2019.02.00310.1016/J.TRECAN.2019.02.003 ↗
20. 10.1038/s41420-019-0200-810.1038/s41420-019-0200-8 ↗
21. 10.1016/J.CELL.2017.01.01810.1016/J.CELL.2017.01.018 ↗
22. 10.1016/J.CCELL.2018.03.02510.1016/J.CCELL.2018.03.025 ↗
23. 10.1016/j.stem.2018.11.01110.1016/j.stem.2018.11.011 ↗
24. 10.3390/CELLS1003065910.3390/CELLS10030659 ↗
25. 10.32604/OR.2024.03100610.32604/OR.2024.031006 ↗
26. 10.1038/s41598-024-75861-910.1038/s41598-024-75861-9 ↗
27. 10.7555/JBR.37.2023024810.7555/JBR.37.20230248 ↗
28. 10.1038/s41392-023-01442-310.1038/s41392-023-01442-3 ↗
29. 10.1016/J.IMMUNI.2018.03.00710.1016/J.IMMUNI.2018.03.007 ↗
30. 10.1186/S13321-015-0055-910.1186/S13321-015-0055-9 ↗
31. 10.1038/s41598-022-09341-310.1038/s41598-022-09341-3 ↗
32. 10.2147/AABC.S6374910.2147/AABC.S63749 ↗
33. 10.1098/RSOS.18100610.1098/RSOS.181006 ↗
34. 10.1111/BPH.1503010.1111/BPH.15030 ↗
35. 10.1016/S1470-2045(00)00292-810.1016/S1470-2045(00)00292-8 ↗
36. 10.1186/S12935-022-02624-910.1186/S12935-022-02624-9 ↗
37. 10.1186/S12967-024-05059-0/TABLES/110.1186/S12967-024-05059-0/TABLES/1 ↗
38. 10.1038/S12276-018-0174-210.1038/S12276-018-0174-2 ↗
39. Dwivedi S Hernández-Montes G Montaño LF Rendón-Huerta EP. Chromosomally Unstable Gastric Cancers Overexpressing Claudin-6 Disclose Cross-Talk between HNF1A and HNF4A and Upregulated Cholesterol Metabolism. Int J Mol Sci. 2022;23(22):13977. doi: 10.3390/ijms232213977.10.3390/ijms232213977 ↗
40. 10.1038/s41388-021-01940-010.1038/s41388-021-01940-0 ↗
41. 10.1038/s41419-024-07099-210.1038/s41419-024-07099-2 ↗
42. 10.3892/IJMM.2018.375610.3892/IJMM.2018.3756 ↗
43. 10.1194/JLR.M600082-JLR20010.1194/JLR.M600082-JLR200 ↗
44. 10.1016/j.tranon.2024.10225010.1016/j.tranon.2024.102250 ↗
45. 10.1016/j.jbc.2022.10263710.1016/j.jbc.2022.102637 ↗
46. 10.1080/21655979.2021.202433210.1080/21655979.2021.2024332 ↗
47. 10.1016/J.GENE.2018.11.03310.1016/J.GENE.2018.11.033 ↗
48. 10.1007/S00018-024-05446-2/FIGURES/610.1007/S00018-024-05446-2/FIGURES/6 ↗
49. 10.18632/ONCOTARGET.2543010.18632/ONCOTARGET.25430 ↗
50. 10.1002/HEP.2785910.1002/HEP.27859 ↗
51. 10.1016/J.XCRM.2023.10117010.1016/J.XCRM.2023.101170 ↗
52. 10.1016/j.ajpath.2015.09.01510.1016/j.ajpath.2015.09.015 ↗
53. 10.1186/S40164-020-00192-010.1186/S40164-020-00192-0 ↗
54. 10.1021/NP50078A016/ASSET/NP50078A016.FP.PNG_V0310.1021/NP50078A016/ASSET/NP50078A016.FP.PNG_V03 ↗
55. 10.1016/J.FITOTE.2010.03.01910.1016/J.FITOTE.2010.03.019 ↗
56. 10.3390/ANTIOX912120710.3390/ANTIOX9121207 ↗
57. 10.3389/FONC.2022.90192210.3389/FONC.2022.901922 ↗
58. 10.2174/187152061866618061111212510.2174/1871520618666180611112125 ↗
59. 10.1186/S40360-021-00540-8/FIGURES/410.1186/S40360-021-00540-8/FIGURES/4 ↗
60. 10.1007/978-3-032-08530-6_810.1007/978-3-032-08530-6_8 ↗
61. 10.1038/s41598-022-11641-710.1038/s41598-022-11641-7 ↗
62. 10.1016/j.biopha.2023.11514810.1016/j.biopha.2023.115148 ↗
63. 10.3389/fphar.2022.85006610.3389/fphar.2022.850066 ↗
64. 10.1038/s41598-025-93120-310.1038/s41598-025-93120-3 ↗
65. 10.3389/fphar.2025.152897810.3389/fphar.2025.1528978 ↗
66. 10.3390/md2207032810.3390/md22070328 ↗
67. Amin Safranal-sorafenib combination therapy for liver cancer; 2019.
68. 10.3390/antiox1106112510.3390/antiox11061125 ↗
69. Crocin-sorafenib combination therapy for liver cancer; 2019.
70. 10.3390/cancers1516406310.3390/cancers15164063 ↗
71. 10.1038/s41598-018-35083-210.1038/s41598-018-35083-2 ↗
72. 10.1016/j.microb.2024.10016510.1016/j.microb.2024.100165 ↗
73. 10.3390/ijms2018457410.3390/ijms20184574 ↗
74. 10.1016/J.DRUDIS.2021.12.01710.1016/J.DRUDIS.2021.12.017 ↗
75. 10.1016/J.CPLETT.2020.13786910.1016/J.CPLETT.2020.137869 ↗
76. 10.3390/ijms24161265110.3390/ijms241612651 ↗
77. 10.3389/fphar.2024.135302910.3389/fphar.2024.1353029 ↗
78. 10.3390/ph1709120810.3390/ph17091208 ↗
79. 10.3390/ph1702020010.3390/ph17020200 ↗